KUKJEON Co.Ltd

KUKJEON Co.Ltd

KKRX:307750
1,860.00
KRW
-39.00
(-2.05%)
-17.63EPS
117.15BMarket Cap
KUKJEON Co.Ltd
KRX:307750
(Korea Stock Exchange)

Recent

price

1,860.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
- -
13,607.54
2,257.34
1,923.53
2,109.49
2,478.35
2,751.03
2,621.47
2,623.48
Revenue per Share
-20.22
724.29
-92.86
91
182
98
35
-86
-36.03
Basic EPS, GAAP
-14.36
-632.14
194.41
-166.21
-605.86
-779.38
-30.69
148.52
205.41
Free Cash Flow per Basic Share
- -
- -
- -
- -
9.98
- -
9.89
9.82
- -
Dividend per Share
1,781.85
3,109.48
776.59
1,694.56
1,866.7
1,965.01
1,985.36
1,919.52
2,088.45
Book Value per Share
1,781.85
3,033.16
766.74
1,685.95
1,839.72
1,936.66
1,886.96
1,823.39
1,996.05
Tangible Book Value per Share
1
5
36
44
49
49
50
50
51
Basic Weighted Avg Shares
- -
73,417
80,623
85,354
103,711
121,998
136,468
131,039
134,572
Sales/Revenue/Turnover
- -
7.69
7.22
7.19
3.38
5.33
0.27
-1.97
1.68
Operating Margin (%)
- -
953
977
1,106
1,444
3,134
5,105
5,227
5,298
Depreciation Expense
-27
3,908
-3,317
4,038
8,948
4,824
1,736
-4,299
-1,848
Net Income, GAAP
- -
15.55
- -
20.58
19.94
- -
38.85
- -
- -
Effective Tax Rate (%)
- -
5.32
-4.11
4.73
8.63
3.95
1.27
-3.28
-1.37
Profit Margin (%)
1,324
3,961
17,223
55,063
72,202
24,169
16,613
8,670
27,418
Working Capital
636
1,057
3,000
1,137
25,293
26,517
24,657
16,073
15,810
LT Debt
9,614
16,777
32,230
83,150
92,323
97,456
97,499
95,872
114,003
Total Equity
- -
19.84
- -
6.98
2.31
- -
0.13
- -
- -
Return on Invested Capital (%)
- -
19.45
- -
6.16
8.62
- -
4.7
- -
- -
Return on Capital (%)
- -
29.62
-13.53
7
10.24
5.13
1.79
-4.44
-1.73
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
29,829
24,279
24,827
LT Borrowings
15,526
15,399
15,272
LT Finance Leases
547
511
538
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
54
54
Market Capitalization
168,843
227,552
117,150

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
74,746
84,000
85,642
Cash, Cash Equivalents & STI
30,549
30,386
33,155
Accounts Receivable, Net
23,291
27,823
29,835
Inventories
18,026
22,816
19,792
Total Current Liabilities
66,076
63,818
58,225
Payables & Accruals
- -
- -
- -
ST Debt
29,829
24,279
24,827
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
34.59%
-1.67%
Free Cash Flow
- -
-111.45%
-587.66%
Net Income, GAAP
- -
-111.57%
-347.6%
Sales/Revenue/Turnover
- -
10.58%
-3.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
39,310
33,704
31,314
32,139
136,468
2025
38,284
33,339
29,205
30,212
131,039
2026
34,672
40,484
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
24
47
-1
-35.15
35
2025
18
2
-57.81
-47.91
-86
2026
-52.28
113
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9.96
- -
- -
- -
9.89
2025
9.94
- -
- -
- -
9.82
2026
- -
- -
- -
- -
- -
Business
KUKJEON Co.,Ltd. is a South Korea-based fine chemical and pharmaceutical manufacturing company specializing in the research, development, synthesis, and commercial supply of active pharmaceutical ingredients, finished drug formulations, and high-purity advanced electronic materials. Founded in 1972 and headquartered in Anyang-si, Gyeonggi-do, South Korea, the company is publicly traded on the KOSDAQ market of the Korea Exchange under ticker 307750. Operating primarily through its Pharmaceutical and Advanced Electronic Materials divisions, the company delivers precision chemical solutions to healthcare providers, pharmaceutical manufacturers, semiconductor fabricators, display panel producers, and energy storage manufacturers across domestic and international markets, including Japan and Europe. The company's primary product and service portfolio encompasses: active pharmaceutical ingredients (APIs), including itopride hydrochloride for functional gastrointestinal disorders, nafamostat mesylate for anticoagulation and acute pancreatitis, as well as synthetic ingredients for cardiovascular, respiratory, antimicrobial, and central nervous system therapeutics; finished dosage pharmaceutical products, comprising ethical prescription pharmaceuticals, incrementally modified drugs, and oral solid-dosage generic medications supplied to hospital and clinic networks; advanced semiconductor materials, notably high-purity precision cleaning agents and chemical precursors engineered for artificial intelligence (AI) semiconductor packaging processes; display and optoelectronic chemicals, consisting of organic light-emitting diode (OLED) intermediate compounds, quantum-dot (QD) OLED anti-reflective film materials, and optical polymers for foldable display applications; and secondary battery materials, including specialized functional electrolyte additives designed to enhance the stability, cycle life, and thermal resistance of electric vehicle batteries. In recent strategic and corporate developments, the company officially changed its corporate name from Kukjeon Pharmaceutical Co., Ltd. to KUKJEON Co.,Ltd. in 2026, broadening its registered corporate objectives to cover precision chemical manufacturing and signaling its structural transformation into an integrated total chemical solution provider. To support its materials portfolio, the company completed and commissioned a KRW 50 billion advanced electronic materials production facility in Eumseong, Chungcheongbuk-do, securing domestic mass-production capabilities for AI semiconductor packaging chemicals and next-generation display components. Within its pharmaceutical operations, KUKJEON secured a commercial API supply agreement with Dongsung Pharmaceutical for the photosensitizer Phonogen and established research and development partnerships with Hanlim Pharm and Dr. InB for photoreactive oncology therapeutics. Additionally, the company expanded its global footprint through KS Biologics, a joint venture established with SN BioScience, by partnering with Germany-based oncology firm Akvida for the European commercialization and distribution of specialized anticancer therapies, alongside collaborating with EniSolution to implement advanced osmotic-release oral system (OROS) drug delivery technologies.